Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF/VEGFR expression and efficacy of bevacizumab + paclitaxel + carboplatin in first-line serous epithelial ovarian carcinoma
2005-003209-10Phase 2Completed
- Sponsor
- Tampere University Hospital
- Start
- Sep 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, paclitaxel and carboplatin in Serous Papillary Cystadenocarcinoma, sponsored by Tampere University Hospital. Primary endpoints: VEGF expression in serous epithelial ovarian carcinoma, VEGFR1 expression in serous epithelial ovarian carcinoma and 1 more. Started Sep 2005; status: completed.
02
Drugs
bevacizumabpaclitaxelcarboplatin
03
Conditions
Serous Papillary Cystadenocarcinoma
Beyond the preview
Go deeper on 2005-003209-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003209-10.